top of page
Supported projects
McSAF Inside Oncology
Is developing a new generation of immunoconjugates targeting CD56+ cancers. Its first candidate is an ADC, designed to deliver a cytotoxic load directly to tumour cells, with a focus on small cell lung cancer and Merkel cell carcinoma.
PSCC's entrance
September 2023
Localization
FR - Centre Val de Loire
Modality
Targeted therapy
Development status
Biotech - Lead optimization
Award(s)
bottom of page